References

References

1. Sastry S, Nyshdham J, Fix J, (2000), Recent technological

advances in oral drug delivery: a review, AAPS Pharm Sci Tech, 3,

138-44.

2. Kaur T, Gill B, Kumar S, Gupta GD (2011), Mouth dissolving

tablets: A novel approach to drug delivery, International Journal of

Current Pharmamecutical Research, 3, 1-7.

3. Yeola B, Pisal S, Paradkar A, Mahadik K, (2000), New drug delivery

system for Elderly. Indian Drugs, 37(7), 312-8.

4. Chang R, Guo X, Burnside B, (2000), A review of fast dissolving

tablets, Pharm Tech, 52-4.

5. Kuchekar BS, Badhan AC, Mahajan HS, (2003), Mouth Dissolving

Tablets: A novel drug delivery system, Pharma Times, 35, 10-7.

6. Chien YW. Novel drug delivery systems. New York – Marcel Dekker

Inc., 2nd ed. 1992.p.139-140.

7. Buck JR, Peck GE, Banker GS. Drug development community,

1975; 1-8.

8. Bandari S, Mittapalli RK, Gannu R, Yamsani MR, (2008),

Orodispersible tablets: An overview, Asian J Pharm, 2(1), 2-11.

9. Jeong SH, Park K, (2008), Material properties for making fast

dissolving tablets by a compression method, Journal of Materials

Chemistry, 18, 3527–3535.

10. McLaughlin R, Banbury S, Crowley K, (2009), Orally Disintegrating

Tablets the Effect of Recent FDA Guidance on ODT Technologies

and Applications, Pharmaceutical Technology, 8(2), 161-172.

11. Bhowmik D, Chiranjib B, Krishnakanth P, Chandira RM. Fast

dissolving tablet: An overview. J Chem. Pharm. Res 2009;1:163-77.

12. Sharma S, (2008), New generation of tablet: Fast dissolving tablet,

Latest review, 6(5).

13. Kumari S, Visht S, Sharma PK, Yadav RK, (2010), Fast dissolving

Drug delivery system : Review Article, Journal of Pharmacy

Research, 3(6), 1444-1449.

References

14. Shukla D, Chakraborty S, Singh S, Mishra B, (2009), Mouth

Dissolving Tablets I: An Overview of Formulation Technology,

Scientia Pharmceutica, 76, 309-326.

15. Hirani JJ, Rathod DA, Vadalia KR, (2009), Orally Disintegrating

Tablets: A Review, Tropical Journal of Pharmaceutical Research,

8(2), 161-172.

16. Chang X, Guo BA, Burnside BA, Couch RA, (2000), review of fast

dissolving tablets, Pharmaceutical Technology, 24(6), 52-58.

17. Van Scoik KG, (1992), Solid Pharmaceutical Dosage in Tablet

Triturate form, 1992; US patent No 5,082,667.

18. Birader SS, Bhagavati ST, Kuppasad IJ, (2006), Fast dissolving

drug delivery systems: a brief overview, The International Journal of

Pharmacology, 4(2).

19. Sayeed A, Mohiuddin MH, (2011), Mouth dissolving tablets: An

Overview, International Journal of Research in Pharmaceutical and

Biomedical Sciences, 2(3), 959-970.

20. Panigrahi R, Behera S, (2010), A Review on Fast Dissolving

Tablets, Webmed Central Quality and patient safety, 1(9),

WMC00809.

21. Amarjit S, Rajesh J. United states Patent No.7122198. Fast

dissolving composition with prolonged sweet taste.

22. Vummaneni V, Chawla L, (2012), Mouth Dissolving Tablets: A

Review, Am J PharmTech Res, 2(3).

23. Rishi RK, (2004), Data Safety Monitoring Board, The Pharma

Review, 2, 32.

24. Prajapati BG, Ratnakar NA, (2009), Review on Recent patents on

Fast Dissolving Drug Delivery System, International Journal

PharmTech Research, 1(3), 790-798.

25. Shailesh S, Gupta GD, Bala R, Sharma N, Seth N, Goswami JP,

(2008), Orodispersible tablet: A review, 03, 29.

26. Abdelbary G, Prinderre P, Eouani C, Joachim J, Reynier JP,

Piccerelle P, (2004), The preparation of orally disintegrating tablets

using a hydrophilic waxy binder, International Journal of Pharma,

278(2), 423-33.

References

27. Bagul U, Gujar K, Patel N, Aphale S, Dhat S, (2010), Formulation

and Evaluation of Sublimed Fast Melt Tablets of Levocetirizine

Dihydrochloride, International Journal of Pharmamecutical

Sciences, 2(2), 76-80.

28. Kalia A, Khurana S, Bedi N, (2009), formulation and evaluation of

mouth dissolving tablets of oxcarbazepine, Int J pharm pharmace

sci, 1, 12-23.

29. Allen LV, Wang B, (2001), Process for making a particulate support

matrix for making a rapidly dissolving dosage form, US patent No

6,207,199.

30. Allen LV, Wang B, Davis JD, (2000), Method for Producing a

Rapidly Dissolving Dosage Form, US Patent No 6066 and 337.

31. Giri T, Tripathi D, Maunder R, (2010), Formulation aspects in the

development of Orodispersible tablets: an Overview, International

Journal Pharm and Pharm Sciences, 2(3), 38-42.

32. Arya A, Chandra A, Sharma V, Pathak K, (2010), Fast Dissolving

Oral Films: An Innovative Drug Delivery System and Dosage Form,

2(1), 576-583.

33. Lieberman HA, Lachman L, Schwartz JB, (1989), Pharmaceutical

dosage forms Tablets, New York, Marcel Deckker, Inc, 1, 131.

34. Reddy LH, Ghose B, Rajneesh, (2002), Fast dissolving drug

delivery systems: a review of the literature, Ind J Pharm Sci, 64(4),

331- 336.

35. Parakh SR, Gothoskar AV, (2003),A Review of Mouth Dissolving

Tablet, Pharma Tech, 92-100.

36. Babu GV, Kumar NR, Himasankar K, Seshasayana A, Murthy KV, (

2003),Nimesulide-modified gum karaya solid mixtures: preparation,

characterization and formulation development, Drug Dev Ind

Pharm, 29, 855-864.

37. Patel TS, Sengupta M, (2013),Fast Dissolving Tablet Technology –

A Review, WJPPS, 2(2), 485-508.

38. Vishwkarma DK, Tripathi AKB, Yogesh P, Maddheshiya B,

(2011),Review article on mouth dissolving film, Journal of Global

Pharma Technology, 3(1), 1-8.

References

39. Profile Resources at Business.com. Cima Labs - Profile. 2001, 27,

5.

40. Seager H, (1998), Drug-deliver Products and the Zydis Fast-

dissolving Dosage Form, J Pharm and Pharmacol, 50, 375-382.

41. Bhattacharya S, Pal TK, A review on Fast Dissolving Tablet

Technology, Pharmatutor.

42. Patel PB, Chaudhary A, Gupta GD, (2006), Fast Dissolving Drug

Delivery Systems: An Update, Pharmainfo.net, 4(4).

43. Jagani H, Patel R, Upadhyay P, Bhangale J, Kosalge S, (2011),

Fast dissolving tablets: present and future prospectus, J Advance

Pharm Healthcare Res, 2(1), 57-70.

44. Manivannan R, (2009),Oral disintegrating tablets: a future

compaction, International Journal of Pharmaceutical Research Dev-

Online, 1(10),1-10.

45. Chatap VK, (2007), Review on taste masking methods for bitter

drug, Pharmainfo Net, 5(1), 45.

46. Sohi H, Sultana Y, Khar RK, (2004),Taste masking technologies in

oral pharmaceutics: recent developments and approaches, Drug

Dev, Ind Pharm, 30(5), 429-48.

47. Reilly WJ, (2002), Remington: The science and practice of

pharmacy, 20th ed., Mack publishing company, 1018-20.

48. Saini S, Nanda A, Hooda M, Komal, Dhari J, (2011), Formulation

and evaluation of mouth dissolving anti-allergic tablets of

Levocitrizine dihydrochloride, J Chem Pharm Res, 3(5), 450-455.

49. Banker GS, Anderson GR, Lachman L, Liberman HA, Karnig JL,

(1987),The theory and practice of a industrial pharmacy, 3rdedition,

Varghese publishing house, Mumbai, 293.

50. Lachman L, Liberman H, Kanig J, (1976),The theory and practice of

industrial pharmacy, 2nd edn. Varghese Publishing House Mumbai,

pp. 297.

51. Amin AF, Shah T, Bhandani M, Patel M, (2007), Emerging trend in

the development of orally disintegrating tablet technology,

pharmainfo.net.

References

52. Younxia B, Sunada H, Yonezawa Y, Danjo K, (1999), Evaluation of

rapid disintegrating tablets prepared by Direct compression method,

Drug Dev Ind Pharm, 25(5), 571.

53. Zhang W, Wang Y, Gao X, Gao X, Peng S, Zheng Y, Okeke CI,

(2013), Optimization of Jiawei Qing’e Oral Fast Disintegrating

Tablets Based on Response Surface-Central Composite Design,

Chinese Herbal Medicines, 5(2), 138-144.

54. Sharma D, (2013), Formulation Development and Evaluation of

Fast Disintegrating Tablets of Salbutamol Sulphate for Respiratory

Disorders, ISRN Pharmaceutics, 1-8.

55. Reddy Mettu S, Reddy Veerareddy P, (2013), Formulation,

Evaluation and Pharmacokinetics of Flurbiprofen Fast Dissolving

Tablets, British Journal of Pharmaceutical Research, 3(4), 617-631.

56. Iyer SR, Sivakumar R, Siva P, Sajeeth CI, (2013), Formulation and

Evaluation of Fast Dissolving Tablets of Risperidone solid

dispersion, IJPCBS, 3(2), 388-397.

57. Elbary AA, Ali AA, Aboud HM, (2012), Enhanced dissolution of

meloxicam from orodispersible tablets prepared by different

methods, Bulletin Facult Pharmacy Cairo Univ, 07,001.

58. Roy H, Parida KR, Nandi S, Panda SK, Mohapatra DK, (2012),

Design of fast dissolving amlodipine besylate tablet formulations,

Asian J Pharm, 6, 51-9.

59. Thakre A, Bhople A, Jaiswal S, Chandewar A, Ghuge N, Wagh N,

Thakre S, Bari M, (2012), Formulation and Development of Oral

Fast Dissolving Tablet of Etoricoxib, Der Pharmacia Lettre, 4(4),

1169-1182.

60. Kaurav A, Jain S, Mishra S, Verma R, (2012), Formulation and

Evaluation of Fast Dissolving Tablet of Levocetrizine using Direct

Compression Technique, AJPER, 1(1), 32-41.

61. Sharma D, Chopra R, Bedi N, (2012), Development and evaluation

of paracetamol taste masked orally disintegrating tablets using

polymer coating technique, International Journal of Pharm Pharm

Sci, 4(3), 129-134.

References

62. Rane DR, Gulve HN, Patil VV, Thakare VM, Patil VR, (2012),

Formulation and evaluation of fast dissolving tablet of albendazole,

International Current Pharmaceutical Journal, 1(10), 311-316.

63. Patel K, Rajendra A, (2012), Design and Evaluation of Mouth

Dissolving Tablets of Anti Hypertensive Drug Telmisartan, Int J

Pharm Tech Res, 4(2), 715-724.

64. Sharma V, Singh L, Saxena P, Kumar JA, (2011), Formulation and

evaluation of mouth dissolving tablets of cefixime, IRJP, 2(5), 171-

174.)

65. Ganure Ashok L, Dangi Amish A , Patel Pinkal Kumar, Manish

Kumar Rai, Aravadiya Jigar P, (2011), Preparation and evaluation

of tramadol hydrochloride fast dispersible tablet by using

compression technique, IJPI’s Journal of Pharmaceutics and

Cosmetology, 1, 2.

66. Solanki SS, Dahima R, (2011), Formulation and evaluation of

aceclofenac mouth-dissolving tablet, J Adv Pharm Technol Res,

2(2), 128–131.

67. Masareddy R, Kokate A, Shah V, (2011), Development of

Orodispersible Tizanidine HCl Tablets Using Spray Dried

Coprocessed Exipient Bases, Indian J Pharm Sci, 2011; 73(4),

392–396.

68. Kumar DS, Reddy BA, Tiwari AK, Swetha B, Dey S, (2011),

Formulation and evaluation of mouth dissolving tablets of

Felodipine, AJPCR, 2011; 4(1).

69. Sharma V, Chopra H (2010), Formulation and Evaluation of Taste

Masked Mouth Dissolving Tablets of Levocetirizine Hydrochloride,

Iranian Journal of Pharmaceutical Research, 11(2), 457-463.

70. Keny RV, Desouza C, Lourenco CF, (2010), Formulation and

evaluation of Rizatriptan Benzoate mouth disintegrating tablets,

Indian J Pharm Sci, 72, 79-85.

71. Sawarikar PP, Sridhar BK, Shivkumar S, (2010), Formulation and

Evaluation of Fast Dissolving/Disintegrating Tablets of Isoxsuprine

Hydrochloride, Journal of Current Pharmaceutical Research, 3(1),

41-46.

References

72. Gnanaprakash K, Mallikarjuna Rao K, Chandra Sekhar KB,

Madhusudhana Chetty C, Alagusundaram M, Ramkanth S, (2009),

Formulation and evaluation of fast dissolving tablets of Valdecoxib,

International Journal of Pharm Tech Research, 1(4), 1387-1393.

73. Parikh R, Ranch KM, Koli AR, (2009), Formulation and optimization

of orodispersible tablets of Atenolol, International Journal of Pharm

tech Res, 1(4), 1559-63.

74. Zade PS, Kawtikwar PS, Sakarkar DM, (2009), Formulation,

evaluation and optimization of fast dissolving tablet containing

Tizanidine Hydrochloride, International Journal of Pharm Tech

Research, 1(1), 34-42.

75. Patel B, Patel D, Parmar R, Patel C, Serasiya T, Sanja SD, (2009),

Development and In vitro Evaluation of Fast Dissolving Tablets of

Glipizide, International Journal of Pharmacy and Pharma Sciences,

1(1), 145-50.

76. Parmar RB, Baria AH, Tank HM, Faldu SD, (2009), Formulation and

Evaluation of Domperidone Fast Dissolving Tablets, International

Journal of Pharm Tech Res, 1(3), 483-487.

77. Jain CP, Naruka PS, (2009), Formulation and Evaluation of Fast

dissolving tablet of Valsartan, International Journal of of Pharm,

1(1), 219-26.

78. Setty CM, Prasad DVK, Gupta VRM, Sa B, (2008), Development of

fast dispersible aceclofenac tablets: Effect of functionality of

superdisintegrant, International Journal of Pharmamecutical

Sciences, 180-185.

79. Dinesh BM, Patel YR, Patil UA, Rajani GP, Desai BG, (2007),

Formulation and evaluation of dispersible tablets of valdecoxib,

Pharma buzz , 2(10), 25-31.

80. Swamy PV, Areefulla SH, Shirsand AB, Gandra S, Prashanth B,

(2007), Orodispersible tablets of Meloxicam using disintegrant

blends for improved efficacy, Indian Journal of Pharm Sciences,

69(6), 836-840.

References

81. Malke S, Shidhaye S, Kadam VJ, (2007), Formulation and

evaluation of oxcarbazepine fast dissolve tablets, Indian Journal of

Pharm Sciences, 69(2), 211-14.

82. Shishu, Bhatti A, (2006), Fast Disintegrating tablets of Diazepam.

Indian drugs, 43(8), 643-648.

83. Kuno Y, Kojima M, Ando S, Nakagami H, (2005), Evaluation of

rapidly disintegrating tablets manufactured by phase transition of

sugar alcohols, J control Release, 105, 16-22.

84. Larry LA, (2005), Functionality comparison of 3 classes of

superdisintegrants in promoting Asprin tablet disintegration and

dissolution, AAPS Pharm Sci Tech, 6(4), 634-640.

85. Lalla JK, Mamania HM, (2004), Fast dissolving rofecoxib tablets,

India J Pharma Sci, 66(3), 350-3.

86. Mahajan HS, Kuchekar BS, Badhan AC, (2004), Mouth dissolving

tablets of Sumatriptan succinate, Indian Journal of Pharm Sciences,

66(2), 238-40.

87. Mahaejan HS, Kuchekar BS, Badhan AC, (2004), Mouth dissolving

tablets of Salbutamol sulphate: A novel drug delivery system, Indian

Drugs, 41(10), 592-98.

88. Kaushik D, Saini TR, Dureja H, (2004), development of melt in

mouth tablets by sublimation technique, Journal of pharmaceutical

research, 3(2), 35-37.

89. Induwade NH, Rayaguru TH, Nakhat PD, (2002), Novel approach-

Fast dissolving tablets, Indian Drugs, 39(8), 405-9.

90. Allen LV, Wang B, (1996), Process for making a particulate support

matrix for making a rapidly dissolving tablet, US patent No

5,587,180.

91. Madoria N, Maheshwari Y, Formulation, (2012), Optimization and

Characterization of Fast Dissolving Tablet of Celecoxib, Research

Journal of Pharmacy and Technology, 5(8), 1085-1088.

92. Pehlivan SB, Subasi B, Vural I, Unlu N, Capan Y, (2011),

Evaluation of drug-excipient interaction in the formulation of

celecoxib tablets, Acta Poloniae Pharmaceutica- Drug Research,

68(3), 423-433.

References

93. Gangawat LK, Sharma SK, Bisht R, (2011), Design and

development of fast dissolving Celecoxib tablet by solid dispersion

and camphor sublimation method using 32 full factorial design,

Pharm Tech, 1, 105-115.

94. Kumar S, (2010), Formulation and evaluation of Celecoxib

orodispensible tablets, RGUHS Journal of Pharmaceutical

Sciences, 11-21.

95. Tiwari V, kinikar DJ, Pillai K, Gokulan PD, (2010), Preparation and

Evaluation of Fast Dissolving Tablets of Celecoxib, Journal of

Current Pharmaceutical Research, 04, 4-10.

96. Dade BK, Chavala AK, (2010), Formulation of celecoxib in to

immediate release tablets, An International Journal of Advances In

Pharmaceutical Sciences, 1(2), 318-26.

97. Kadian SS, Kumar A, Dennis DM, Diwan A, (2010), Formulation

design and evaluation of floating matrix tablet of celecoxib by direct

compression, Int j ph sci, 2(2), 556-560.

98. Pandya VM, Patel DJ, Patel JK, Patel RP, (2009), Formulation,

Characterization and Optimization of Fast-Dissolve Tablets

Containing Celecoxib Solid Dispersion, Dissolution Technologies,

22-27.

99. Chandran S, Punnarao R, Saha RN, (2006), Development and In

vitro Evaluation of Oral Controlled Release Formulaitons of

Celecoxib Using Optimization Techniques, The Pharmaceutical

Society of Japan, 126(7), 505-514.

100. Jani P, Vadalia K, Bagdai H, Dedania R, Manseta P, (2012),

Formulation and evaluation of controlled release floating

microspheres of tolperisone hydrochloride, Asian J Pharm, 6, 190-

7.

101. Soni R, Patel M, Patel K, Patel N, (2012), Formulation & in vitro

evaluation of floating tablet of tolperisone hcl, IJPS, 3(4), 2477-

2492.

102. Martindale, (1993), The Extra Pharmacoepia, 30th edition, 1211.

103. Hofer D, Lohberger B, Steinecker B, Schmidt K, Quasthoff S,

Schreibmayer W, (2006), A comparative study of the action of

References

tolperisone on seven different voltage dependent sodium channel

isoforms, Eur J Pharmacol, 538 (1-3), 5–14.

104. Primo FT, Froehlich PE, (2005), Celecoxib Identification Methods,

Acta Farm Bonaerense, 24 (3), 421-5.

105. Krishnaveni G, Sathyannaryana PVV, (2012), A novel RP-HPLC

method for the quantification of Celecoxib in formulations, Research

Journal of Pharmaceutical, Biological and Chemical Sciences, 3(1),

340-346.

106. Yelland MJ, Nikles CJ, McNairn N, Del Mar CB, Schluter PJ, Brown

RM, (2007), Celecoxib compared with sustained release

paracetamol for osteoarthritis: a series of n-of-1 trials,

Rheumatology, 46(1), 135–40.

107. Tanaka R, Hirayama N, (2007), Structure of Tolperisone

hydrochloride, Analytical Sciences: X-ray Structure Analysis Online,

23, 85-89.

108. Kocsis P, Farkas S, Fodor L, Bielik N, Than M, Kolok S, Gere A,

Csejtei M, Tarnawa I, (2005), Tolperisone-type drugs inhibit spinal

reflexes via blockade of voltage-gated sodium and calcium

channels, J Pharmacol Exp Ther, 315 (3), 1237–1246.

109. Cims India, Update – 3, July – October 2011, pp 39.

110. Indian Pharmacopoeia, Vol. II, New Delhi, The Controller

Publication, Govt. of India, 2010, 1199.

111. British Pharmacopoeia, Vol. I, London, The British Pharmacopoeia

Commission, 2010, 672.

112. Japanese Pharmacopeia, 15th ed, Society of Japanese

Pharmacopeia, 2006, 1190-1191.

113. Welzig S, Rothenburger J, Kalz B, Gungl J, Gerdes K, (2010),

Tolperisone controlled release tablet, European patent, 2, 228 056

114. Gabrielsson J, lindberg NO, Lundstedt T, (2002), Multivariate

methods in pharmaceutical applications, Journal of Chernometrics,

16, 141-160,

115. Maryadele J O’ Neil, (2006), The Merck Index: An Encyclopedia of

chemicals, drugs and biologicals, 14th edition. New Jersey:

References

Published by Merck Research Laboratories, Division of Merck and

Co., Inc, Whitehouse station, 1698.

116. Murali M, Satyanarayana PV, (2011), Simple validated isocratic RP-

HPLC method for estimation of tolperisone in bulk and

pharmaceutical dosage form, Der Pharm Chemica, 3, 13-19.

117. Koladia BB, Vaghela VM, (2012), UV spectroscopic method for

quantitative estimation of tolperisone hydrochloride in bulk and

pharmaceutical dosage form, International Journal of PharmTech

Res, 4, 1317-22.

118. Liawruangrath S, Liawruangrath B, Pibool P, (2001), Simultaneous

determination of tolperisone and lidocaine by HPLC, J Pharm

Biomed Anal, 26, 865-72.

119. Sharma KK, Patel PU, (2012), First derivative spectroscopic

method for simultaneous estimation of paracetamol and tolperisone

in their combined dosage form, Journal of Pharmaceutical Sciences

and Biosciences Research, 2, 92-96.

120. Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Vargas R,

Davis B, Day R, Ferraz MB, Hawkey CJ, Hochberg MC, Kvien TK,

Schnitzer TJ, Weaver A, (2000), Comparison of upper

gastrointestinal toxicity of rofecoxib and naproxen in patients with

rheumatoid arthritis, VIGOR Study Group, New Eng J Med, 343,

1520-24.

121. Fung HB, Kuschenbaum HL, (1999), Clin Therap, 7, 1131-57.

122. Howard PA, Delafontaine P, (2004), Nonsteroidal anti-

Inflammatory drugs and cardiovascular risk, Journal of American

Coll Cardiol, 43, 519-25.

123. Lane JM, (2002), Antiinflammatory medications: selective COX-2

inhibitors, Journal American Academy of Orthopeadic Surgery, 10,

75-78.

124. Yazici AC, Baz K, Ikizoglu G, Kolturk A, Uzumlu H, Tataroglu C,

(2004), Celecoxib induced photoallaergic drug eruption,

International Journal of Dermatology, 43(6), 459 – 461.

References

125. Pentland AP, Schoggins JW, Scoh GA, Khan KNM, Han R, (1999),

Reduction of UV-induced skin tumors in hairless mice by selective

COX-2 inhibition, Carcinogenesis, 20(10), 1939 – 1944.

126. Lu Z, Xiong X, Zhang B, Lin G, Shi Y, Liu Z, Meng J, Zhou Y, Mei

Q, (2005), Evaluation of 2 celecoxib derivatives: analgesic effect

and selectivity to cyclooxygenase-2/1, Acta Pharmacologica Sinica,

26(12), 1505 – 1511.

127. Adegbolagun OM, Adelowo FA, (2011), Ultraviolet irradiation of

Celecoxib: Absence of adverse biological effect, Nigerian Journal

Pharm Sci, 10(1), 6 –15.

128. Nagarsenker MS, Joshi MS, (2005), Celecoxib-cyclodextrin

systems: characterization and evaluation of in vitro and in vivo

advantage, Drug Dev Ind Pharm, 31, 169-78.

129. Pehlivan SB, Suba B, Vural I, Unlu N, Capan Y, (2011), Evaluation

of drug-excipient interaction in the formulation of Celecoxib tablets,

Acta Poloniae Pharmaceutica n Drug Research, 68, 3, 423-433.

130. Baboota S, Agarwal SP, (2002), Inclusion complexation of

meloxicam with beta cyclodextrin, Indian J Pharm Sci, 64(4), 408–

411.

131. Fricker J, Varkalis J, Zwillich S, Adler R, Forester E, Recker DP,

Verburg KM, (2002), Valdecoxib is more efficacious than rofecoxib

in relieving pain associated with oral surgery, American Journal of

Therapy, 9(2), 89–97.

132. Camu F, Beecher T, Recker DP, Verburg KM, (2002), Valdecoxib, a

cox-2-specific inhibitor, is an efficacious, opioid-sparing analgesic in

patients undergoing hip arthroplasty, Am J Ther, 9(1), 43–51.

133. Dannhardt G, Kiefer W, (2001), Cyclooxygenase inhibitors - current

status and future prospects, European Journal of Medicinal

Chemistry, 36(2), 109–126.

134. McMurray RW, Hardy KJ, (2002), Cox-2 inhibitors: today and

tomorrow, Am J Med Sci, 323, 181.

135. Kornblum SS, Stoopak SB, (1973), A new tablet disintegrating

agent: crosslinked polyvinylpyrrolidone, Journalof Pharmaceutical

Sciences, 62, 43-49.

References

136. Rudnic EM, Lausier JM, Chilamkurti RN, Rhodes CT, (1980),

Studies of the utility of cross linked polyvinylpolypyrrolidine as a

tablet disintegrant, Drug Dev Ind Pharm, 6, 291- 309.

137. Gordon MS, Chowhan ZT, (1987), Effect of tablet solubility and

hygroscopicity on disintegrant efficiency in direct compression

tablets in terms of dissolution, Journal of Pharmaceutical Sciences,

76, 907–909.

138. Gordon MS, Rudraraju VS, (1993), Effect of the mode of super

disintegrant incorporation on dissolution in wet granulated tablets, J

Pharm Sci, 82, 220– 226.

139. Tagawa M, Chen R, Chen P, (2003), Effect of various disintegrants

on drug release behavior from tablets, J Pharm Sci Tech

Yakuzaigaku, 63(4), 238– 248.

140. Hipasawa N, Ishise S, Miyata M, Danjo K, (2004), Application of

nilvadipine solid dispersion to tablet formulation and manufacturing

using crospovidone and methylcellulose on dispersion carriers,

Chem Pharm Bull, 52(2), 244–247.

141. Schiermeier S, Schmidt PC, (2002), Fast dispersible ibuprofen

tablets, European Journalof Pharmaceutical Sciences, 15(3), 295–

305.

142. Thibert R, Hancock BC, (1996), Direct visualization of

superdisintegrant hydration using environmental scanning electron

microscopy, Journal of Pharmaceutical Sciences, 85, 1255–1258.

143. Caraballo I, Milan M, Rabasco AM, (1997), Influence of disintegrant

on the drug percolation threshold in tablets, Drug Dev Ind Pharm,

23(7), 665–669.

144. Yen SY, Chen CR, Lee MT, Chen LC, (1997), Investigation of

dissolution enhancement of nifedipine by deposition on

superdisintegrants, Drug Dev Ind Pharm, 23(3), 313–317.

145. Hirai N, Ishikawa K, Takahashi K, (2006), Improvement of the

agitation granulation method to prepare granules containing a high

content of a very hygroscopic drug, J Pharm Pharmacol, 56, 1437–

1441.

References

146. Newton JM, Razzo FN, (1975), Interaction of formulation factors

and dissolution fluid and the in vitro release of drug from hard

gelatin capsule, J Pharm Pharmacol, 27, 78.

147. Stewart AG, Grant DJW, Newton JM, (1979), The release of a

model low-dose drug (riboflavine) from hard gelatin capsule

formulations, J Pharm Pharmacol, 31, 1–6.

148. Chowhan ZT, Chi LH, (1986), Drug–excipient interactions resulting

from powder mixing III: solid state properties and their effect on

drug dissolution, J Pharm Sci, 75, 534–541.

149. Botzolakis JE, Augsburger LL, (1988), Disintegrating agents in hard

gelatin capsules part 1: mechanism of action, Drug Dev Ind Pharm,

14(1), 29–41.

150. Hannula AM, Marvola M, Jons M, (1989), Release of ibuprofen from

hard gelatin capsule formulations: effect of modern disintegrants,

Acta Pharm Fenn, 98, 189–196.

151. Marvola M,Hannula AM, Ojantakanen S, Westermarck E, Rajamaki

M, (1989), Effect of sodium bicarbonate and sodium starch

glycolate on the in vivo disintegration of hard gelatin capsules – a

radiological study in the dog, Acta Pharm Nord, 1, 355–362.

152. Khan KA, Rooke DJ, (1976), Effect of disintegrant type upon the

relationship between compressional pressure and dissolution

efficiency, J Pharm Pharmacol, 28, 633–636.

153. Rubinstein MH, Price EJ, (1977), In vivo evaluation of the effect of

five disintegrants on the bioavailability of frusemide from 40 mg

tablets, J Pharm Pharmacol, 29, 5.

154. Caramella C. The influence of disintegrants on the characteristics of

coated acetylsalicylic acid tablets. Farmaco (Prat) 1978; 33: 498–

507.

155. Gebre Mariam T, Winnemöller M, Schmidt PC, (1996), Evaluation

of the disintegration efficiency of a sodium starch glycolate

prepared from enset starch in compressed tablets, Eur J Pharm

Biopharm, 42(2), 124–132.

References

156. Cid E, Jaminet F, (1971), Influence of adjuvants on the dissolution

rate and stability of acetylsalicylic acid in compressed tablets, J

Pharm Belg, 26, 38–48.

157. Bolhuis GK, Van Kamp HV, Lerk CF, (1986), On the similarity of

sodium starch glycolate from different sources, Drug Dev Ind

Pharm, 12(4), 621–630.

158. Rudnic EM, Kanig JL, Rhodes CT, (1985), Effect of molecular

structure variation on the disintegrant action of sodium starch

glycolate, J Pharm Sci, 74, 647–650.

159. Bolhuis GK Arends-Scholte AW, Stuut GJ, de Vries JA, (1984),

Effect of variation of degree of substitution, crosslinking and purity

on the disintegrant efficiency of sodium starch glycolate, Acta

Pharm Technol, 30, 24–32.

160. Claudius JS, Neau SH, (1996), Kinetic and equilibrium

characterization of interactions between glycopeptide antibiotics

and sodium carboxymethyl starch, International Journal of

Pharmacy, 144, 71–79.

161. Claudius JS, Neau SH, (1998), The solution stability of vancomycin

in th presence and absence of sodium carboxymethyl starch, Int J

Pharm, 168, 41–48.

162. Kibbe AH, (2000), Handbook of pharmaceutical excipients:

Cellulose, silicified microcrystalline, American Public Health

Association, Washington.

163. Luukkonen P, Schaefer T, Hellen J, Juppo AM, Yliruusi J, (1999),

Rheological characterization of microcrystalline cellulose and

silicified microcrystalline cellulose wet masses using a mixer torque

rheometer, International Journal of Pharmaceutics, 188, 181–192.

164. Edge S, Steele F, Chen A, Tobyn M, Staniforth JN, (2000), The

mechanical properties of compacts of microcrystalline cellulose and

silicified microcrystalline cellulose, International Journal of

Pharmaceutics, 200, 67–72.

165. Van Veen B, Bolhuis GK, Wu YS, Zuurman K, Frijlink HW, (2005),

Compaction mechanism and tablet strength of unlubricated and

References

lubricated (silicified) microcrystalline cellulose, European Journal of

Pharmaceutics and Biopharmaceutics, 59, 133–138.

166. Sherwood BE, Becker JW, (1998), A new class of high functionality

excipients: Silicified microcrystalline cellulose, Pharmaceutical

Technology, 22, 78–88.

167. Guo M, Augsburger LL, (2003), Potential application of silicified

microcrystalline cellulose in direct-fill formulations for automatic

capsule-filling machines, Pharmaceutical Development and

Technology, 8, 47– 59.

168. Zografi G, Kontny MJ, Yang AYS, Brenner GS, (1984), Surface

area and water vapor sorption of microcrystalline cellulose,

International Journal of Pharmaceutics, 18, 99–116.

169. Hwang RC, Peck GR, (2001), A systematic evaluation of the

compression and tablets characteristics of various types of

microcrystalline cellulose, Pharmaceutical Technology, 24, 112–

132.

170. Muzikova J, Novakova P, (2007), A study of the properties of

compacts from silicified microcrystalline celluloses, Drug

Development and Industrial Pharmacy, 33, 775–781.

171. Fleming K, Gray DG, Matthews S, (2001), Cellulose Crystallites,

Chem Eur J, 7, 1831-1835.

172. Microcrystalline Cellulose, In: European Pharmacopoeia. 4 th

edition (2002), Strasbourg, France, Council of Europe.

173. Azizi Samir MAS, Alloin F, Dufresne A, (2005), A Review of Recent

Research into Cellulosic Whiskers, their Properties and their

Application in Nanocomposite Field, Biomacromolecules, 6, 612-

626.

174. Leppänen K, Anderson S, Torkkeli M, Knaapila M, Kotelnikova N,

Serimaa R, (009), Structure of Cellulose and Microcrystalline

Cellulose from Various Species, Cotton and Flax Studied by X-Ray

Scattering, Cellulose, 16, 999-1015.

175. Lachman L, Lieberman HA, Kanig JL, (1987), Tablet. In: Banker

GS, Anderson NR, editors. The Theory and Practice of Industrial

References

Pharmacy, 3rd Indian Ed. Bombay: Varghese Publishing House,

299–329.

176. Prabhu Halakatti K, Omer S, Gulgannavar SR, Kumar PP, (2010),

Formulation and evaluation of mouth disintegrating tablets of

famotidine by using Hibiscus Ros Sinensis mucilage and treated

agar, International Journal of Research in Ayurveda and Pharmacy,

1(2), 497–505.

177. Mehta KK, Patel HH, Patel ND, Vora CN, Patel NJ (2010),

Comparative evaluation of natural and synthetic superdisintegrant

for promoting nimesulide dissolution for fast dissolving technology,

International Journal of Pharmacy and Pharmaceutical Sciences,

2(3), 102–108.

178. Gokul Ghenge G, Pande SD, Ahmad A, Jejurkar L, Birari T, (2011),

Development and characterisation of fast disintegrating tablet of

amlodipine besylate using mucilage of plantago ovata as a natural

superdisintegrant, International Journal of PharmTech Research,

3(2), 938–945.

179. Prabakaran L, Sendhil D (2011), Formulation development of

patient friendly dosage form: all in one natural excipient as binder,

diluent and disintegrant, International Journal of Pharmacy and

Pharmaceutical Sciences, 3(2), 97–102.

180. Disintegration and dissolution tests. II. New Delhi: Controller of

Publications; 1996. Indian Pharmacopoeia; pp. A80–5. Appendix 7.

181. Klancke J, (2003), Dissolution testing of orally disintegrating

tablets, Diss Technol, 10, 6–8.

182. Jadhav SB, Kaudewar DR, Kaminwar GS, Jadhav AB, Kshirsagar

RV, Sakarkar DM, (2011), Formulation and evaluation of dispersible

tablets of diltiazem hydrochloride, International Journal of

PharmTech Research, 3(3), 1314–1321.

183. Metker V, Kumar A, Pathak N, Padhee K, Sahoo S, (2011),

Formulation and evaluation of orodispersible tablets of

lornoxicam, International Journal of Drug Development and

Research, 3(1), 281–285.

References

184. Arya A, Sharma S, Kumar J, Chandra A, Jaiswal P, (2010),

Formulation and evaluation of mouth dissolving tablets of ranitidine

HCL, International Journal of Pharm Tech Research, 2(2), 1574–

1577.

185. Kulkarni U, Rao NGR, (2011), Design and development of

Aceclofenac fast dissolving tablets by amorphous solid dispersion

technique using modified Marmelos gum,” International Journal of

Pharmaceutical Research and Development, 3(6), 201–210.

186. Setia A, Goyal N, Kansal S, (2011), Formulation and evaluation of

ciprofloxacin hydrochloride dispersible tablets using natural

substances as disintegrates, Pelagia Research Library Der

Pharmacia Sinica, 2(1), 36–39.

187. Abdul Ahad H, Sreenivsulu R, Reddy KK, Kavitha K, Sumapadmaja

B, Reddy VK, (2011), Isolation and characterization of Ficus indica

fruit mucilage, Journal of Pharmacy Research, 4(3), 726–727.

188. Kumar R, Patil S, Patil MB, Patil SR, Paschapur MS, (209),

Isolation and evaluation of disintegrant properties of fenugreek seed

mucilage, International Journal of PharmTech Research, 1(4), 982–

996.

189. Senthilnathan B, Rupenagunta A, (2011), Formulation development

and evaluation of venlafaxine hydrochloride orodispersible

tablets, International Journal of Pharmaceutical Sciences and

Research, 2(4), 913–921.

190. Anjankumar PB, Nazmuddin M, Kulkarni U, Hariprasanna RC,

(2011), Formulation and evaluation of lornoxicam fast dissolving

tablet, International Research Journal of Pharmacy, 2(4), 130–133.

191. Mohire NC, Yadav AV, (2010), Novel approach to formulate β-

cyclodextrin complexed mouth dissolving tablet of metronidazole

and its in-vitro evaluation, Journal of Pharmacy Research, 3(3),

662–667.

192. Nayak SM, Gopalkumar P, (2004), Design and optimization of fast

dissolving tablets for promethazine theoclate, Indian Drugs, 41,

554-6.

References

193. Gohel M, Patel M, Amin A, Agrwal R, Dave R, Bariya N, (2004),

Formulation design and optimization of mouth dissolve tablets of

nimesulide using vaccum drying technique, AAPS Pharm Sci Tech,

5, 1-6.

194. Kuchekar BS, Badhan AC, Mahajan HS, (2004), Mouth dissolving

tablets of salbutamol sulphate: A novel drug delivery system, Indian

Drugs, 41, 592-8.

195. Siddiqui MN, Garg G, Sharma PK, (2010), Fast dissolving tablets:

Preparation, characterization and evaluation: An overview.

International Journal of Pharmaceutical Sciences Review and

Research, 4(2), 87-96.

196. Puttalingaiah L, Kavitha K, Mani TT, (2011), Fast disintegrating

tablets: An Overview of Formulation, Technology and Evaluation.

Res J Pharmaceutical Biological Chem Sci, 2(2), 589-601.

197. Chaudhary Sunita A, Chaudhary Ankit B, Mehta Tejal A, (2010),

Excipients Updates for Orally Disintegrating Dosage Forms.

International Journal of Research Pharmaceutical Sciences,

1(2),103-107.

198. Goel Honey, Rai Parshuram, Rana Vikas, Tiwary Ashok K, (2008),

Orally Disintegrating Systems: Innovations in Formulation and

Technology. Recent Patents on Drug Delivery and Formulation, 2,

258-274.

199. Gupta A, Mishra AK , Gupta V , Bansal P, Singh R, Singh AK

(2010), Recent Trends of Fast Dissolving Tablet-An Overview of

Formulation Technology. International Journal of Pharmaceutical &

Biological Archives, 1(1):1-10.

200. Srivastava Saurabh, Bala Rajni, Joshi Baibhav, Rana AC, Singla

Vikas, (2012), Mouth dissolving tablet:Afuture compaction.

International Research Journal of Pharmacy, 3(8), 98-109.

201. Mishra B, Panigrahi D, Baghel S, (2005), Mouth dissolving tablets:

An overview of preparation techniques, evaluation and patented

technologies, J Pharm Res, 4, 33-8.

202. Gothoskar AV, Parakh SR, (2003), A Review of mouth dissolving

tablet technologies, Pharmaceutical Technology, 27, 92-100.

References

203. William RP, Ghosh TK, (2005), Orally disintegrating tablets.

Pharmaceutical Technology (Product, Technologies, and

Development issues in Oct 2005).

204. Wayne C, Dipan R, Ann D, (2006), Selecting superdisintegrants for

Orally Disintegrating Tablet, Formulations in Phrmaceutical

Technology, 08, 226-229.

205. Jadon RS, Vaidya VD, Khemariya P, Nayak S, (2009), Taste

Masking of Lornoxicam by Polymer Carrier System and Formulation

of Oral Disintegrating Tablets, IJDD, 1, 1-3

206. Biradar SS, (2006), Fast dissolving drug delivery systems: a brief

overview, The Internet Journal of Pharmacology, 4(2).

207. Ghosh T, Ghosh A, Prasad D, (2011), A Review on new generation

orodispersible tablets and its future prospective, International

Journal of Pharmacy and Pharmaceutical Sciences, 3(1), 1-7.

208. Agrawal VA, Rajurkar RM, Thonte S, Ingale RG, (2011), Fast

disintegrating tablets as a new drug delivery system: a review,

Pharmacophore, 2(1), 1-8.

209. Deshmekh KR, Vidyanand P, Shekhar V, Alok P, Pramod KD

(2011), A review on mouth dissolving tablet techniques, Int J Res

Ayurveda Pharm, 2(1), 66-74.

210. Monachandran PS, Sindhumol PG, Kiran TS (2011),

Superdisintegrants: An overview, J Pharm Sci Rev Res, 6(1), 105-

109.

211. Reeta RT, Mridul K (2011), An unlimited scope for novel

formulations as orally disintegrating systems: Present and future

prospects, J Appl Pharm Sci, 1(1), 13-19.

212. Ishikawa T, Mukai B, Shiraishi S, Naoki U, (1999), Preparation and

evaluation of tablets rapidly disintegrating in saliva containing bitter

taste masked granules by the compression method, Chem Pharm

Bull, 47(10), 1451-1454.

213. Yoshio K, Masazumi K, Shuichi A, Hiroaki N, (2008), Effect of

preparation method on properties of orally disintegrating tablets

made by phase transition, Int J Pharm, 355, 87–92.

References

214. Battue SK, Repay MA, Maunder S, Rio MY, (2007), Formulation

and evaluation of rapidly disintegrating tablet Fenoverine tablets:

Effect of superdisintegrants, Drug Dev Ind Pharm, 33, 1225-1232.

215. Bi Y, Sunada H, Yonezawa Y, Danjo K, Otsuka A, Iida K, (1996),

Preparation and evaluation of a compressed tablet rapidly

disintegrating in the oral cavity, Chem Pharm Bull (Tokyo), 44,

2121-2127.

216. Sreenivas SA, Gadad AP, Dandagi PM, Mastiholimath VS, Patil

MB, (2006), Formulation and Evaluation of Ondansetron HCl

Directly Compressed Mouth Disintegrating Tablets, Indian Drugs,

43, 35-37.

217. Kundu S, Sahoo PK, (2008), Recent trends in the developments of

orally disintegrating technology. Pharma Times, 40(4), 11-15.

218. Chakraborthy S, Khandai M, Singh SP, Patra N, (2008),

Comparative study on effect of natural and synthetic

superdisintegrant in the formulation of fast dissolving tablet,

International Journal of Green Pharmacy, 9, 22-25.

219. Gudas GK, Manasa B, Rajesham VV, Kumar SK, Prasanna

Kumari J, (2010), Formulation and evaluation of fast dissolving

tablets of Chlorpromazine HCl, J Pharm Sci Tech, 1, 99-102.

220. Kakade SM, Mannur VS, Ramani KB, Dhada AA, Naval CV,

Bhagwat A, (2010), Formulation and evaluation of mouth dissolving

tablets of losartan potassium by direct compression techniques, Int

J Res Phar Sci, 1(3), 290-295.

221. Mizumoto T, Masuda Y, Kajiyama A, Yanagisawa M, Nyshadham

JR, (2003), Tablets quickly disintegrating in the oral cavity and

process for producing the same, US Patent 6,589,554.

222. Yourong F, Shicheng Y, Seong HJ, Susumu K, Kinam P, (2004),

Orally Fast Disintegrating tablets: Developments, technologies,

Taste-masking and clinical studies, Critical review in therapeutic

drug carrier systems, 21(6), 433–475.

223. Percel PJ, Venkatesh GM, Vishnupad KS, (2001), Functional

coating of linezolid microcapsules for taste-masking and associated

formulation for oral administration, WO Patent 0,152,848.

References

224. Ishikawa T, Watanabe Y, Utoguchi N, Matsumoto M, (1999),

Preparation and evaluation of tablets rapidly disintegrating in saliva

containing bitter-taste-masked granules by the compression

method, Chem Pharm Bull, 47(10), 1451–1454.

225. Mishra DN, Bindal M, Singh SK, Kumar SGV, (2005), Rapidly

disintegrating oral tablets of meloxicam, Indian Drugs, 42(10), 685-

687.

226. Morita Y, Tsushima Y, Yasui M, Termoz R, Ajioka J, Takayama K,

(2002), Evaluation of the disintegration time of rapidly disintegrating

tablets via a novel utilizing a CCD camera. Chem & Pharma

Bulletin, 50(9), 1181–1186.

227. Ashwini KG, Choudhary RK, Chaitanya CH, (2011), Enhancement

of Solubility and Dissolution Rate of Irbesartan by Solid Dispersion

Technique, Asian Journal of Pharmceutical Clinical Research, 4(2),

364.

228. Jadhav SB, Kaudewar DR, Kaminwar GS, Jadhav AB, Kshirsagar

RV, Sakarkar DM, (2011), Formulation and evaluation of dispersible

tablets of diltiazem hydrochloride, International Journal of

PharmTech Research, 3(3), 1314–1321.

229. Metker V, Kumar A, Pathak N, Padhee K, Sahoo S, (2011),

Formulation and evaluation of orodispersible tablets of

lornoxicam, International Journal of Drug Development and

Research, 3(1), 281–285.

230. Mizumoto T, Masuda Y, Fukui M, (1996), Intrabuccally dissolving

compressed moldings and production process thereof, US Patent

5,576,014.

231. Milovac J, Kovacic M, Kopitar Z, Urbancic-Smerkolj J, Lenardic A,

Zorz M, (1991), Dispersible tablets of dihydroergotoxine

methanesulfonate and of acid addition salts thereof, US Patent

5,047,247.

232. Yourong F, Shicheng Yang, Seong HJ, Susumu K, Kinam P,

(2004), Orally Fast Disintegrating Tablets: Developments,

Technologies, Taste-Masking and Clinical Studies, Critical

Reviews™ in Therapeutic Drug Carrier Systems, 21(6), 433–475.

References

233. Parkash V, Maan S, DeepikaYadav SK, Hemlata, Jogpal V, (2011),

Fast disintegrating tablets: Opportunity in drug delivery system, J

Advanced pharma Techno & Res, 2(4), 223-35.

234. Kulkarni U, Rao R, (2011), Design and development of aceclofenac

fast dissolving tablets by amorphous solid dispersion technique

using modified Aegle marmelos gum. Int J Pharma Res Dev, 3(6),

201-210.

235. Mathur P, Saroha K, (2010), Mouth dissolving tablets: An overview

on future compaction in oral formulation technologies, Der

Pharmacia Sinica, 1(1), 179-187.

236. Aithal K, Harish NM, Rathnanand M, Shirwaikar A, Dutta M, (2006),

Once daily fast dissolving tablets of granisetron hydrochloride

formulation and in vitro evaluation. Indian Drugs, 43(7), 576-581.

237. Sharma Deepak, Kumar Dinesh, Singh Mankaran, Singh Gurmeet,

Rathore MS, (2012), Fast Disintegrating Tablets: A New Era in

Novel Drug Delivery System & New Market Oppor- tunities.Journal

of Drug Delivery & Therapeutics, 2(3), 74-86.

238. Arya A, Sharma S, Kumar J, Chandra A, Jaiswal P, (2010),

Formulation and evaluation of mouth dissolving tablets of ranitidine

HCL, International Journal of Pharm Tech Research, 2(2), 1574–

1577.

239. Senthilnathan B, Rupenagunta A, (2011), Formulation development

and evaluation of venlafaxine hydrochloride orodispersible

tablets, International Journal of Pharmaceutical Sciences and

Research, 2(4), 913–921.

240. Yoshio K, Masazumi K, Shuichi A, Hiroaki N, (2005), Evaluation of

rapidly disintegrating tablets manufactured by phase transition of

sugar alcohols, J Control Release, 105, 16-22.

241. Mohire NC, Yadav AV, (2010), Novel approach to formulate β-

cyclodextrin complexed mouth dissolving tablet of metronidazole

and its in-vitro evaluation, Journal of Pharmacy Research, 3(3),

662–667.

References

242. Nayak SM, Gopalkumar P, (2004), Design and optimization of fast

dissolving tablets for promethazine theoclate, Indian Drugs, 41,

554-6.

243. Gohel M, Patel M, Amin A, Agrwal R, Dave R, Bariya N, (2004),

Formulation design and optimization of mouth dissolve tablets of

nimesulide using vaccum drying technique, AAPS Pharm Sci Tech,

5, 1-6.

244. Camu F, Beecher T, Recker DP, Verburg KM, (2002), Valdecoxib, a

cox-2-specific inhibitor, is an efficacious, opioid-sparing analgesic in

patients undergoing hip arthroplasty, American Journal Therapy,

9(1), 43–51.

245. Dannhardt G, Kiefer W, (2001), Cyclooxygenase inhibitors - current

status and future prospects, European Journal of Medicinal

Chemistry, 36(2), 109–126.

246. McMurray RW, Hardy KJ, (2002), Cox-2 inhibitors: today and

tomorrow, Am J Med Sci, 323, 181.